RxDoctor Payments Data

Charoen Mankongpaisarnrung, MD

Gastroenterology · Saint Paul, MNNPI 1649567926

Payments from drug & device makers

$757in general payments, 2019–2025

Across 34 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$533
  • Takeda Pharmaceuticals U.S.A., Inc.$82
  • Gilead$77
  • Johnson & Johnson$34
  • Digestive Care, Inc.$16
  • Ironwood Pharmaceuticals, Inc$14

What the payments were for

  • Food & beverage$757100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie19$533
Takeda Pharmaceuticals U.S.A., Inc.5$82
Gilead6$77
Johnson & Johnson2$34
Digestive Care, Inc.1$16
Ironwood Pharmaceuticals, Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$757 in reported general payments places this provider in the 55th percentile of 365 gastroenterology providers in Minnesota.

See all gastroenterology providers in Minnesota

Medicare billing

Part B allowed, 2024
$48,917
Medicare patients
214
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab29$771,485
Omeprazole283$5,776
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl258$5,613
Mesalamine13$5,139
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl65$1,339
CholestyramineCholestyramine (With Sugar)11$1,018
Famotidine18$998
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl50$967
Mirtazapine14$643
Pantoprazole Sodium51$630
Fluconazole20$518
Ondansetron Hcl270$455
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$267
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg11$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$34$771,48529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 365 gastroenterology providers in Minnesota.

Other gastroenterology in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →